TABLE 2.

Descriptive characteristics of 17 women with ankylosing spondylitis, stratified by menopausal status

Characteristics	Postmenopausal women, n = 11 (64.7%)	Premenopausal women, n = 6 (35.3%)	P‐value
Age, years	58.0 (53.0–63.0)	42.5 (38.5–47.5)	<.001**
BMI, kg/m2	26.4 (22.8–29.8)	23.8 (23.0–24.8)	.1
Ever smoker	6 (54.5)	1 (16.7)	.3
Symptom duration, years	34.0 (30.0–39.0)	19.5 (17.8–22.8)	<.001**
HLA‐B27‐positive	11 (100)	6 (100)	NA
ESR, mm/h	16.0 (8.0–28.0)	4.5 (1.8–10.8)	.03*
hsCRP, mg/L	2.8 (0.8–7.0)	2.2 (0.6–2.9)	.4
IL‐22, pg/mL (n = 16)	0.47 (0.18–0.64)	0.22 (0.12–0.49)	.2
IL‐10, pg/mL (n = 17)	0.23 (0.14–0.26)	0.15 (0.11–0.19)	.1
History of anterior uveitis	6 (54.5)	3 (50.0)	1.0
History of peripheral arthritis	6 (54.5)	4 (66.7)	.6
ASDAS‐CRP, score	1.9 (1.5–2.2)	1.1 (0.9–1.9)	.05*
BASDAI, score	4.5 (3.4–5.6)	3.0 (1.8–4.4)	.05*
BASFI, score	2.6 (1.2–4.2)	1.4 (0.8–3.4)	.3
BASMI, score	3.4 (2.6–4.4)	2.5 (2.0–3.0)	.03*
NSAID, regular use	6 (54.5)	5 (83.3)	.3
csDMARD	0 (0)	0 (0)	NA
bDMARD	0 (0)	2 (33.3)	.1
csDMARD and/or bDMARD	0 (0)	2 (33.3)	.1
mSASSS, score	3.0 (0.0–8.0)	0.0 (0.0–1.2)	.05*
Syndesmophyte presence	4 (36.4)	0 (0)	.2

Note: Values presented as median with interquartile range (IQR) or number of patients and percent (%).

Abbreviations: ASDAS, Ankylosing Spondylitis Disease Activity Score; b, biologic; BASDAI, Bath Ankylosing Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BMI, body mass index; csDMARD, conventional synthetic disease‐modifying anti‐rheumatic drug; ESR, erythrocyte sedimentation rate; HLA‐B27, human leucocyte antigen B27; hsCRP, high‐sensitivity C‐reactive protein; mSASSS, Modified Stoke Ankylosing Spondylitis Score; NSAID, non‐steroidal anti‐inflammatory drug. *P ≤ .05; **P ≤ .005.